Lewy Bodies Study for Those Experiencing Visual Hallucinations (VH)

Official Title
A Phase 2, double-blind, randomized, placebo-controlled cross-over study of nelotanserin versus placebo in Lewy body dementia (LBD) subjects experiencing visual hallucinations (VH)
Purpose

Purpose: To assess the safety of using a drug called nelotanserin with those who have dementia with Lewy body with visual hallucinations.

Could this study be right for you?

--Age: 50-85
--Diagnosis: dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD), presence of visual hallucinations that occur more days than not.
--MMSE Score: greater than or equal to 18 (Mini-Mental State Exam--Coordinator will explain)
--Must have a study partner willing to attend visits and ensure compliance with the study

Age Range
50 and up

Lewy Bodies Study for Those with Sleep Behavior Disorders

Official Title
A Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) experiencing REM sleep behaviors (RBD)
Purpose

The purpose of this study is to evaluate the safety of the study drug called nelotanserin and to assess the effects of nelotanserin in those experiencing frequent REM sleep behavior disorders due to dementia with Lewy bodies. Nelotanserin (study drug) is an investigational product, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) or the government health agencies of any other countries.

Could this study be right for you?

--Age: 50-85
--Diagnosis: probable dementia with Lewy bodies or Parkinson's disease dementia
--AND diagnosis of REM sleep behavior disorder (RBD) with frequent RBD episodes
--Must have a study partner willing to serve as a collateral informant for study assessments
--MMSE Score: greater than or equal to 18 (Mini Mental State Examination score to be explained by the coordinator)

Age Range
50 and up

Lewy Bodies Study--Assessing the Effects of a Drug Called RVT-101

Official Title
A Phase 2b, double-blind, randomized, placebo-controlled study of RVT-101 in subjects with dementia with Lewy bodies (DLB)
Purpose

Purpose of Study:
This research study is being done to test a drug called RVT-101. Our researchers want to assess the effects of RVT-101 versus placebo on function including attention, working memory, reaction time, as well as other measures of cognition in patients with DLB.
RVT-101 is an investigational drug. Investigational means that the drug tested in this study has not been approved by the U.S. Food and Drug Administration (FDA) or any other Health Authority including European or Canadian Health Authorities.

Could this study be right for you?

--Ages 50-85
--Diagnosis of Probable dementia with Lewy bodies
--Must have a study partner willing to attend visits and ensure compliance with the study
--Score on MMSE of 14-26 (Mini–Mental State Examination--the study coordinator can explain this)

Age Range
50 and up

A Study to Better Understand Fainting--The ENCHANT Study--seeking healthy 12-20 year olds

Official Title
Electrographic and Neurohormonal Characteristics of Adolescent Nausea during Tilt Table Testing, The ENCHANT Study
Purpose

Researchers are looking for healthy young volunteers in order to understand what happens when someone faints. They want to know about changes in children and teenagers who frequently faint, and compare those who faint to healthy people who do not normally faint.

Researchers want to learn more about what happens to the brain and the stomach when people faint. The electroencephalogram or EEG measures brainwaves. The electrogastrogram or EGG records stomach electrical activity. The goal of this study is to measure how gastric electricity changes during fainting. They will use the EEG to confirm that fainting happened. Researchers will compare results of those who are healthy to patients who faint.

Some individuals with fainting or frequent lightheadedness can have excessive nausea. This is'orthostatic nausea', which means nausea with standing. The purpose of this study is to measure hormones from the blood and electrical changes in the stomach during tilt-table testing in patients and healthy controls. Researchers hope to identify the physiologic changes that lead to orthostatic nausea.

Could this study be right for you?

- Ages 12-20
- No prior fainting or frequent dizziness/lightheadedness
- No prior anxiety or depression
- No medicines that can affect dizziness/lightheadedness
- No difficulties with nausea or abdominal pain
- Normal weight-

Age Range
12 and up

EMERGE- A Study to Evaluate the Effectiveness and Safety of a Medication (Aducanumab) in Those with Early Alzheimer's

Official Title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease Alternate Official Title: 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)
Purpose

The EMERGE study will assess the safety and potential effectiveness of an investigational medication to determine whether it can slow the progression of symptoms in early Alzheimer's Disease, such as memory loss.

Find on CT.gov- https://clinicaltrials.gov/ct2/show/study/NCT02484547?term=EMERGE&rank=…

Could this study be right for you?

In order to qualify you must:
- Be between 50-85 years of age
- Be experiencing symptoms that might be related to early Alzheimer's disease, such as problem with memory or thinking clearly

Additional eligibility criteria will be explained by study staff contact

Age Range
50 and up

A Medication Study for Those with Relapsing Forms of Multiple Sclerosis

Official Title
A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Forms of Multiple Sclerosis.
Purpose

This study is being done to determine how effective an investigational new drug (Ublituximab) is when given to those who have multiple sclerosis and what side effects may happen. Ublituximab has not yet been approved by the United States Food and Drug Administration (FDA), and is for use in clinical trials for people with relapsing forms of multiple sclerosis. The purpose of this clinical trial is to determine what dose and effect the study drug, Ublituximab, has on Multiple Sclerosis (MS) and those who have MS.

Could this study be right for you?

- Ages 18-55
- Diagnosis of Relapsing Multiple Sclerosis
- 2 or more relapses in prior 2 years or 1 relapse in the year prior to screening
- Active disease
- Other eligibility criteria to be discussed during screening

Age Range
18 and up

Medication Study for those with Remitting Relapsing Multiple Sclerosis who have not responded to other Treatments (Ages 18-55)

Official Title
AN OPEN-LABEL STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE HAD A SUBOPTIMAL RESPONSE TO AN ADEQUATE COURSE OF DISEASE-MODIFYING TREATMENT
Purpose

The purpose of this study is to determine the effectiveness of the drug ocrelizumab in those with Remitting Relapsing Multiple Sclerosis who have not had good outcomes with other Disease-Modifying Treatment.

Could this study be right for you?

You may be eligible for this study if you:
- are between the ages of 18 and 55 years
- have a definite diagnosis of Relapsing Remitting MS
- have a length of disease duration (from first symptom) of less than or equal to 8 years
- have been treated with no more than 2 prior disease-modifying treatments (discontinued due to lack of efficiency)

Age Range
18 and up

Medication Study for those with Relapsing Remitting Multiple Sclerosis (Ages 18-65)

Official Title
A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis
Purpose

The purpose of this study is to evaluate the long-term safety and tolerability of a drug (ALKS 8700) used to treat adults with Relapsing Remitting Multiple Sclerosis.

Could this study be right for you?

You may be eligible for this study if you:
- are between 18 and 65 years of age
- have a confirmed diagnosis of Relapsing Remitting Multiple Sclerosis
- EDSS score of 0.0-6.0 at screening and visit 2

Age Range
18 and up

Medication Study for those with Relapsing Multiple Sclerosis (Ages 18-55)

Official Title
AN OPEN-LABEL, MULTICENTER, BIOMARKER STUDY TO EXPLORE THE MECHANISM OF ACTION OF OCRELIZUMAB AND B-CELL BIOLOGY IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
Purpose

The purpose of this study is to determine exactly how the drug Ocrelizumab interacts with human cells to produce its intended effect in those with Relapsing Multiple Sclerosis (RMS).

Could this study be right for you?

You may be eligible for this study if you:
- have been diagnosed with Relapsing Multiple Sclerosis
- have an EDSS score of 0-5.5, inclusive, at screening, and a disease duration less than 15 years if EDSS > 5.0
- are either treatment-naïve or receiving treatment with disease-modifying therapies
- have had at least one clinically documented relapse in the past year and/or at least one T1-weighted Gd- enhancing lesion in the past year and/or at least one new T2 lesion in the past year at the time of enrollment

Age Range
18 and up